Enspryng (satralizumab)
An approved treatment for Neuromyelitis Optica Spectrum Disorder and Thyroid Eye Disease.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Satralizumab wherever you encounter it, plus the key facts at a glance.
- Generic name
- Satralizumab
- Brand name
- Enspryng
- Development code
- SA237
- Drug class
- IL-6 receptor antagonist
- Manufacturer
- Genentech (Roche), developed by Chugai
- How it's taken
- An injection under the skin from a prefilled syringe or, since June 2026, an autoinjector.
A self-injected antibody that blocks the interleukin-6 receptor, approved in August 2020 for anti-AQP4 antibody positive neuromyelitis optica spectrum disorder and in October 2026 for adults with thyroid eye disease, where it is the first treatment people can inject at home.
A third use, MOG antibody-associated disease, is under FDA review with a decision due January 10, 2027.
The decision is expected by January 10, 2027. One email when it is public, with what it means in plain language, plus new trials for MOG Antibody-Associated Disease and FDA news. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Satralizumab fits
In NMOSD it is one of 4 approved targeted drugs, alongside the complement blockers Soliris and Ultomiris and the B-cell drug Uplizna, and the only one patients inject themselves.
- In thyroid eye disease it is the third approved drug and the first that does not block IGF-1R, trading lower responder rates in its trials than Tepezza and Lumvoa reported in theirs for a monthly at-home injection and no hearing warning.
How Satralizumab works
Interleukin-6 is an immune messenger that keeps inflammation going and helps B cells turn into the plasma cells that make harmful antibodies. Satralizumab is an antibody that sits on the IL-6 receptor so the messenger cannot deliver its signal. Its engineering is what sets it apart from the older IL-6 receptor drug tocilizumab: a recycling design lets each satralizumab molecule bind the receptor strongly and repeatedly, which Genentech says gives sustained IL-6 inhibition and supports dosing every 4 weeks.
In NMOSD that calms the attacks on the optic nerves and spinal cord. In thyroid eye disease, where IL-6 levels rise with disease activity, the same block is meant to quiet the inflammation that swells the tissue behind the eye.
Side effects and safety
- Infections. Serious and potentially fatal infections have occurred with IL-6 receptor blockers; hepatitis B and tuberculosis screening before the first dose, no live vaccines.
- Liver enzymes. ALT and AST checked every 4 weeks for 3 months, then every 3 months for a year.
- Low neutrophils. Neutrophil count checked 4 to 8 weeks after starting; dosing paused if it falls too low.
- Hypersensitivity. Allergic reactions including anaphylaxis can occur.
- Hepatitis B and TB tests before the first dose
- Liver enzymes every 4 weeks for 3 months, then every 3 months for 1 year
- Neutrophil count 4 to 8 weeks after starting
The label carries no boxed warning. Its warnings are the ones shared by IL-6 receptor blockers: an increased risk of infections including serious and potentially fatal ones, raised liver enzymes, lowered neutrophil counts and hypersensitivity reactions. Patients are screened for hepatitis B and tuberculosis before the first dose, liver enzymes are checked every 4 weeks for the first 3 months and then every 3 months for a year, neutrophils are checked 4 to 8 weeks after starting, and live vaccines are not given during treatment.
The most common side effects in the NMOSD trials (at least 15%) were nasopharyngitis, headache, upper respiratory infection, gastritis, rash, joint pain, limb pain, fatigue and nausea. In the 2 thyroid eye disease trials, the side effects seen in at least 5% of people on Enspryng and more often than on placebo were upper respiratory infection (5.3% against 2.4%) and a rise in the liver enzyme ALT (5.3% against 0.8%).
Through week 24, ALT or AST rose above normal in 25.2% on Enspryng against 7.3% on placebo in SatraGO-1, and in 11.5% against 4.8% in SatraGO-2, mostly to no more than 3 times the upper limit and without any rise in bilirubin. Neutrophil counts fell in 28.2% against 9.7%, and below 1 x 10^9/L in 2.3% against none, without serious infections.
There were no serious infections on Enspryng, against a rate of 1.9 per 100 patient-years on placebo[6]. Serious adverse events occurred in 4.5% and 3.1% of patients on satralizumab in the 2 trials against 3.2% and 4.8% on placebo, with no deaths[10]. No hearing problems were reported, and the label carries no hearing warning, which separates it from the IGF-1R drugs for thyroid eye disease.
In the METEOROID trial in MOGAD, the side effects seen in at least 5% of people on Enspryng and more often than on placebo were injection-related reactions (16%), flu (9%), joint pain (9%), back pain (9%), sinusitis (7%) and diarrhea (6%)[5].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Satralizumab
An injection under the skin from a prefilled syringe or, since June 2026, an autoinjector. The first 3 doses are given at weeks 0, 2 and 4, then one dose every 4 weeks. For neuromyelitis optica spectrum disorder each dose is 120mg. For thyroid eye disease the dose follows body weight: 120mg for people weighing 40 to 100kg and 180mg, from a 180mg autoinjector, for people over 100kg.
Its safety and effectiveness in thyroid eye disease patients under 40kg have not been established[6]. After training by a healthcare professional, patients or caregivers inject it at home, and the pen can stay out of the refrigerator for up to 8 days.
Prescribing Enspryng? REMS, monitoring and prior authorization criteria for prescribers
Availability and cost
Only available as the brand-name product.
A specialty biologic sold by Genentech. The copay program covers commercially insured patients and the Genentech Patient Foundation covers eligible uninsured patients; Genentech's disclosed list price is $18,905.57 per 120mg syringe (wholesale acquisition cost as of July 1, 2026).
Help paying for Enspryng
With private insurance, the drugmaker's copay card can lower what you pay for Enspryng. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 8 charity funds for the conditions it treats, 6 were open on October 26, 2026. People on Medicare may still qualify for the drugmaker's free medicine program. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.
- Copay help
Genentech co-pay program for commercially insured patients taking Enspryng for an FDA-approved use; eligibility criteria and benefit limits apply. Not valid under federal or state programs.
For: private insurance · source - Free medicine program
Genentech Patient Foundation gives free Genentech medicine to people without insurance coverage or with financial concerns who meet income requirements. People whose health plan or employer requires them to apply to a patient assistance program are not eligible. Call 888-941-3331.
For: no insurance, underinsured, private insurance, Medicare, Medicaid · source - Insurance and case manager help
Genentech Access Solutions handles benefits checks, prior authorization help and referrals to independent co-pay foundations for patients with government insurance.
For: private insurance, Medicare, Medicaid · source
Good to know: Enspryng is now approved for NMOSD and, since October 2026, thyroid eye disease. Genentech's October 16, 2026 approval announcement directs people prescribed Enspryng to Genentech Access Solutions at (866) 422-2377.
Charity funds
- From a charity · Good DaysNeuromyelitis Optica Spectrum Disorder fundOpen
Pays for: Copays for FDA-approved medications (plus travel for some funds), up to $2,100 per year. Requires health insurance (any kind).
The foundation says: “Program Status: open.” - From a charity · NORD RareCareNMOSD Medical Assistance fundOpen
Pays for: Medical and medication costs.
The foundation says: “Accepting Applications” - From a charity · NORD RareCareNMOSD Premium Copay Assistance fundOpen
Pays for: Insurance premiums and copays.
The foundation says: “Accepting Applications” - From a charity · The Assistance FundNeuromyelitis Optica Spectrum Disorder (NMOSD) fundOpen
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
- From a charity · TotalAssist (formerly PAN Foundation)Neuromyelitis Optica Spectrum Disorder fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $8,000 per year. Requires health insurance (any kind).
- From a charity · The Assistance FundThyroid Eye Disease (TED) fundOpen
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
Every program and charity fund for Neuromyelitis Optica Spectrum Disorder →
Access and eligibility
Approved for adults with neuromyelitis optica spectrum disorder who test positive for anti-AQP4 antibodies, and for adults with thyroid eye disease whether the disease is active or chronic. Use in MOG antibody-associated disease is not yet approved and is under FDA review. Patients with active hepatitis B or untreated latent tuberculosis cannot take it.
Source: Enspryng patient site, Genentech
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
NMOSD approval rested on 2 Phase 3 trials, SAkuraStar (satralizumab alone) and SAkuraSky (added to existing immunosuppressants), both of which cut the risk of relapse in anti-AQP4 antibody positive patients[1][2]. For thyroid eye disease, the identically designed Phase 3 trials SatraGO-1 (NCT05987423, 131 patients) and SatraGO-2 (NCT06106828, 127 patients) measured the share of active-disease patients whose eye bulging improved by at least 2mm at week 24.
SatraGO-2 met its primary endpoint, 52.9% versus 23.4% on placebo (p = 0.0011), while SatraGO-1 did not, 49.0% versus 31.2% (p = 0.0715). In SatraGO-2, 89.6% versus 63.3% achieved a 2-point drop in clinical activity score and 60.7% versus 25.8% improved in double vision, and in SatraGO-1 the inflammation measures still favored the drug significantly (78.0% versus 54.9% for the activity score)[8][9][10].
In SatraGO-2 the response across active and inactive disease together was 46.9% against 22.2%[6]. Genentech and Roche said the approval for thyroid eye disease rests on the totality of data from both trials[4]. For MOG antibody-associated disease, the Phase 3 METEOROID trial cut the risk of relapse by 68%, with 87% of treated patients relapse-free at 48 weeks against 67% on placebo[7].
Development history
Satralizumab was created by Chugai Pharmaceutical in Japan as SA237, a re-engineered successor to tocilizumab with recycling antibody technology, and is sold by Genentech and Roche. The FDA approved it as Enspryng on August 14, 2020 for anti-AQP4 antibody positive NMOSD, the first self-injected treatment for that disease; it is now approved in about 90 countries[2][3].
The thyroid eye disease trials began in late 2023, their primary results were presented at the ASOPRS meeting in October 2025, and the FDA accepted a supplemental application with priority review on June 29, 2026, setting a decision date of October 15, 2026[3]. Genentech and Roche announced on October 16, 2026 that the FDA had approved it for adults with thyroid eye disease regardless of how active the disease is or how long it has lasted, the second approved use and the first at-home injection for the disease[4][6].
A second supplemental application, for MOG antibody-associated disease, was accepted with priority review on September 9, 2026 with a decision due January 10, 2027[7].
Explore Neuromyelitis Optica Spectrum Disorder and Thyroid Eye Disease trials
Other Neuromyelitis Optica Spectrum Disorder & Thyroid Eye Disease treatments
Common questions about Satralizumab
▸What is Satralizumab (Enspryng)?
A self-injected antibody that blocks the interleukin-6 receptor, approved in August 2020 for anti-AQP4 antibody positive neuromyelitis optica spectrum disorder and in October 2026 for adults with thyroid eye disease, where it is the first treatment people can inject at home. A third use, MOG antibody-associated disease, is under FDA review with a decision due January 10, 2027.
▸How does Satralizumab work?
Interleukin-6 is an immune messenger that keeps inflammation going and helps B cells turn into the plasma cells that make harmful antibodies. Satralizumab is an antibody that sits on the IL-6 receptor so the messenger cannot deliver its signal. Its engineering is what sets it apart from the older IL-6 receptor drug tocilizumab: a recycling design lets each satralizumab molecule bind the receptor strongly and repeatedly, which Genentech says gives sustained IL-6 inhibition and supports dosing every 4 weeks. In NMOSD that calms the attacks on the optic nerves and spinal cord. In thyroid eye disease, where IL-6 levels rise with disease activity, the same block is meant to quiet the inflammation that swells the tissue behind the eye.
▸What are the side effects of Satralizumab?
The label carries no boxed warning. Its warnings are the ones shared by IL-6 receptor blockers: an increased risk of infections including serious and potentially fatal ones, raised liver enzymes, lowered neutrophil counts and hypersensitivity reactions. Patients are screened for hepatitis B and tuberculosis before the first dose, liver enzymes are checked every 4 weeks for the first 3 months and then every 3 months for a year, neutrophils are checked 4 to 8 weeks after starting, and live vaccines are not given during treatment. The most common side effects in the NMOSD trials (at least 15%) were nasopharyngitis, headache, upper respiratory infection, gastritis, rash, joint pain, limb pain, fatigue and nausea. In the 2 thyroid eye disease trials, the side effects seen in at least 5% of people on Enspryng and more often than on placebo were upper respiratory infection (5.3% against 2.4%) and a rise in the liver enzyme ALT (5.3% against 0.8%). Through week 24, ALT or AST rose above normal in 25.2% on Enspryng against 7.3% on placebo in SatraGO-1, and in 11.5% against 4.8% in SatraGO-2, mostly to no more than 3 times the upper limit and without any rise in bilirubin. Neutrophil counts fell in 28.2% against 9.7%, and below 1 x 10^9/L in 2.3% against none, without serious infections. There were no serious infections on Enspryng, against a rate of 1.9 per 100 patient-years on placebo[6]. Serious adverse events occurred in 4.5% and 3.1% of patients on satralizumab in the 2 trials against 3.2% and 4.8% on placebo, with no deaths[10]. No hearing problems were reported, and the label carries no hearing warning, which separates it from the IGF-1R drugs for thyroid eye disease. In the METEOROID trial in MOGAD, the side effects seen in at least 5% of people on Enspryng and more often than on placebo were injection-related reactions (16%), flu (9%), joint pain (9%), back pain (9%), sinusitis (7%) and diarrhea (6%)[5].
▸How is Satralizumab taken?
An injection under the skin from a prefilled syringe or, since June 2026, an autoinjector. The first 3 doses are given at weeks 0, 2 and 4, then one dose every 4 weeks. For neuromyelitis optica spectrum disorder each dose is 120mg. For thyroid eye disease the dose follows body weight: 120mg for people weighing 40 to 100kg and 180mg, from a 180mg autoinjector, for people over 100kg. Its safety and effectiveness in thyroid eye disease patients under 40kg have not been established[6]. After training by a healthcare professional, patients or caregivers inject it at home, and the pen can stay out of the refrigerator for up to 8 days.
▸Is Satralizumab FDA approved?
Yes, Satralizumab (Enspryng) is FDA approved (2020) for the treatment of Neuromyelitis Optica Spectrum Disorder and Thyroid Eye Disease.
▸Is Enspryng approved for thyroid eye disease?
Yes. Genentech and Roche announced on October 16, 2026 that the FDA approved Enspryng for adults with thyroid eye disease, whether the disease is active or chronic. It is the first treatment for the disease that people can inject at home. The approval came although 1 of its 2 Phase 3 trials, SatraGO-1, missed its primary endpoint; the other, SatraGO-2, met it.
▸How is Enspryng given?
As an injection under the skin at weeks 0, 2 and 4, then every 4 weeks, from a prefilled syringe or autoinjector that patients or caregivers use at home after training. The dose is 120mg, except for people with thyroid eye disease who weigh more than 100kg, who take 180mg.
▸What did the Enspryng thyroid eye disease trials show?
In SatraGO-2, 52.9% of patients with active disease had their eye bulging improve by at least 2mm at week 24 against 23.4% on placebo. In SatraGO-1 the figures were 49.0% and 31.2%, which did not reach statistical significance. Inflammation scores fell significantly on the drug in both trials, and no new safety problems appeared.
▸Does Enspryng cause hearing loss?
No hearing problems were reported in the thyroid eye disease trials, and its label, after 6 years of NMOSD use, carries no hearing warning, including the October 2026 version that added thyroid eye disease. The 2 other approved thyroid eye disease drugs, Tepezza and Lumvoa, both warn of hearing loss that can be permanent.
▸When is the FDA decision on Enspryng for MOGAD?
January 10, 2027. Genentech announced on September 9, 2026 that the FDA had granted that application priority review. It rests on the METEOROID trial, in which Enspryng cut the risk of relapse by 68%.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. National Library of Medicine, DailyMed · 2026-06-22. Enspryng (satralizumab-mwge) injection: prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64c156a4-9bad-4d45-a294-0733c141f47b
- Genentech · 2020-08-14. FDA approves Genentech's Enspryng for neuromyelitis optica spectrum disorder. https://www.gene.com/media/press-releases/14873/2020-08-14/fda-approves-genentechs-enspryng-for-neu
- Genentech · 2026-06-29. FDA grants priority review to Genentech's Enspryng for thyroid eye disease. https://www.gene.com/media/press-releases/15118/2026-06-29/fda-grants-priority-review-to-genentechs
- F. Hoffmann-La Roche via GlobeNewswire · 2026-10-16. FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED). https://www.globenewswire.com/news-release/2026/10/16/3382249/0/en/fda-approves-roche-s-enspryng-a-first-in-class-il-6r-inhibitor-as-the-first-and-only-at-home-subcutaneous-treatment-option-for-thyroid-eye-disease-ted.html
- Genentech · 2026-04-21. Genentech's Enspryng reduces risk of relapse in MOGAD (METEOROID Phase 3). https://www.gene.com/media/press-releases/15108/2026-04-21/genentechs-enspryng-satralizumab-reduces
- Genentech. Enspryng (satralizumab-mwge) injection: prescribing information, revised October 2026 to add thyroid eye disease. https://www.gene.com/download/pdf/enspryng_prescribing.pdf
- Genentech · 2026-09-09. U.S. FDA grants priority review for Genentech's Enspryng for MOG antibody-associated disease. https://www.gene.com/media/press-releases/15124/2026-09-09/us-fda-grants-priority-review-for-genent
- ClinicalTrials.gov · 2026-07-31. SatraGO-1: satralizumab in participants with moderate-to-severe thyroid eye disease, posted results. https://clinicaltrials.gov/study/NCT05987423
- ClinicalTrials.gov · 2026-08-12. SatraGO-2: satralizumab in participants with moderate-to-severe thyroid eye disease, posted results. https://clinicaltrials.gov/study/NCT06106828
- Ophthalmology. Efficacy and safety of satralizumab for thyroid eye disease: week 24 results from the Phase 3 SatraGO-1 and SatraGO-2 randomized trials. https://doi.org/10.1016/j.ophtha.2026.08.039
- Genentech · 2026-07-01. Enspryng wholesale acquisition cost disclosure. https://www.drugpricinglaw.com/content/dam/gene/drugpricinglaw/pdfs/Genentech-Enspryng.pdf